Abstract
It is increasingly being recognized that breast cancer does not represent a single homogeneous disease; instead, the hormone-receptor status defines important clinical and etiologic differences. We review the epidemiologic data on differences in risk-factor associations by hormone-receptor status and highlight major trends in the literature. We discuss the development and evaluation of breast cancer risk models, with a focus on the Rosner and Colditz model, which can separately estimate the risk of hormone-receptor-positive and hormone-receptor-negative breast cancers. We also discuss the clinical implications of accounting for hormone-receptor status in breast cancer risk-prediction models.
Original language | English |
---|---|
Pages (from-to) | 415-423 |
Number of pages | 9 |
Journal | Nature Clinical Practice Oncology |
Volume | 4 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2007 |